The top lawyer for global biopharma company Catalent Inc., which has produced more than a billion COVID-19 vaccines and treatments, is shifting to a newly created administrative role as part of an organizational restructuring following the appointment of a new CEO. 

Steven Fasman is shedding the general counsel and senior VP titles he’s held since 2014, and taking over as executive VP and chief administrative officer, according to an announcement Tuesday. 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]